You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Investigational Drug Information for Neridronic Acid


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Neridronic Acid?

Neridronic Acid is an investigational drug.

There have been 4 clinical trials for Neridronic Acid. The most recent clinical trial was a Phase 3 trial, which was initiated on December 20th 2016.

The most common disease conditions in clinical trials are Syndrome, Reflex Sympathetic Dystrophy, and Complex Regional Pain Syndromes. The leading clinical trial sponsors are Grünenthal GmbH and [disabled in preview].

There is one US patent protecting this investigational drug and thirteen international patents.

Recent Clinical Trials for Neridronic Acid
TitleSponsorPhase
Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS)Grünenthal GmbHPhase 3
Efficacy and Safety of Intravenous Neridronic Acid in CRPSGrünenthal GmbHPhase 3
Safety of Intravenous Neridronic Acid in CRPSGrünenthal GmbHPhase 3

See all Neridronic Acid clinical trials

Clinical Trial Summary for Neridronic Acid

Top disease conditions for Neridronic Acid
Top clinical trial sponsors for Neridronic Acid

See all Neridronic Acid clinical trials

US Patents for Neridronic Acid

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Neridronic acid ⤷  Try a Trial Method of diagnosing and treating cancer using B-catenin splice variants The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) ⤷  Try a Trial
Neridronic acid ⤷  Try a Trial Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) ⤷  Try a Trial
Neridronic acid ⤷  Try a Trial Use of inhibitors of Bruton'S tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA) ⤷  Try a Trial
Neridronic acid ⤷  Try a Trial Use of inhibitors of Bruton's tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA) ⤷  Try a Trial
Neridronic acid ⤷  Try a Trial Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome ANTECIP BIOVENTURES II LLC (New York, NY) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Neridronic Acid

Drugname Country Document Number Estimated Expiration Related US Patent
Neridronic acid Australia AU2006213610 2025-02-10 ⤷  Try a Trial
Neridronic acid Canada CA2596845 2025-02-10 ⤷  Try a Trial
Neridronic acid Denmark DK1851340 2025-02-10 ⤷  Try a Trial
Neridronic acid European Patent Office EP1851340 2025-02-10 ⤷  Try a Trial
Neridronic acid Hong Kong HK1115165 2025-02-10 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.